Abstract. Platelet-endothelial cell adhesion molecule-1 or CD31 (PECAM-1/CD31) is a receptor recognized by Plasmodium falciparum-parasitized erythrocytes (pRBCs). Fluorescence-labeled soluble recombinant PECAM-1/ CD31 (sPECAM-1/CD31) is shown to bind to the surface of P. falciparum-infected erythrocytes on up to 70% of the cells. Binding is blocked by the addition of the unlabeled receptor in a dose-dependent fashion, but not by unrelated receptor-proteins. A significant correlation was found between the binding of sPECAM-1/CD31 to pRBCs and the binding to transfected L cells expressing the receptor as seen with six different P. falciparum lines or clones. Panning of cultures on PECAM-1/CD31 transfected L cells was paralleled by an increase in the binding of sPECAM-1/CD31. The pRBCs of 54% of fresh patient-isolates bound sPECAM-1/CD31 with a mean rate of 12.9% (range ϭ 1.1-44%). The data suggest that PECAM-1/CD31 is a common receptor recognized by wild isolates and that the soluble PECAM-1/CD31 suspension assay is a sensitive and reliable way to study PECAM-1/CD31 binding.
INTRODUCTION
Malaria infection caused by Plasmodium falciparum has two unique features that separate it from other forms of human malaria: sequestration of parasitized red blood cells (pRBCs) in the microvasculature and the occurrence of severe pathologic complications. 1 It is generally believed that the two phenomena are linked and that massive adhesion of pRBCs to the vascular endothelium may lead to occlusion of the microvasculature and thereby play an important role in the pathogenesis of cerebral malaria. 2, 3 Furthermore, the inflammatory response with the production of cytokines, such as tumor necrosis factor-␣ 4,5 and nitric oxide, 6 has been suggested to participate in the pathogenesis of the disease.
Examining laboratory-selected parasites in cell cytoadherence assays has identified a number of endothelial cell receptors. These include the adhesion molecules CD36, 7 platelet-endothelial cell adhesion molecule-1 (PECAM-1/CD31), 8 intercellular adhesion molecule-1, (ICAM-1), 9 thrombospondin (TSP), 10 and glycosaminoglycan chondroitin sulfate A (CSA). 11 Ex vivo, CD36 is the most frequent target of strains from patients with mild as well as severe P. falciparum malaria, but it is expressed at low levels on the cerebral vasculature. 3 Therefore, it has been proposed that CD36 is unlikely to be involved in the evolution of cerebral disease. In a recent study on the Kenyan coast, we have shown that disease severity is associated with adhesion of pRBCs to multiple receptors rather than one single receptor (Heddini A and others, unpublished data). In this context, any receptor might, together with the right co-receptors, be of importance in disease severity.
We previously described the binding of pRBCs to the endothelial receptor PECAM-1/CD31 in vitro. 8 This receptor is a 130-kD glycoprotein belonging to the immunoglobulin superfamily that is expressed on endothelial cells, leukocytes, platelets, and some T cell subsets. 12 It is important for maintaining endothelial integrity and also for the process of diapedesis, in which leukocytes traverse the endothelium as they are recruited to a site of inflammation. In both of these cases PECAM-1/CD31 interacts homophilically with other PECAM-1/CD31 molecules. However, heterophilic interactions between PECAM-1/CD31 and other structures have also been demonstrated. 13 We have shown that pRBCs adhere to the N-terminal part of PECAM-1/CD31 and that this binding is mediated by the cysteine-rich inter-domain region (CIDR) and Duffy binding like domain-2␦ (DBL-2␦) of P. falciparum erythrocyte membrane protein 1 (PfEMP1). 14 However, it is likely that additional parasite-derived ligands expressed on the surface of pRBCs may also contribute to this binding since treatment of pRBCs with trypsin in concentrations that will cleave off PfEMP-1 does not completely abrogate PECAM-1/CD31 binding. 15, 16 Since the common assays for investigating cytoadherence are dependent on parasitemia to a large extent, we have developed an assay in which soluble fluorescent PECAM-1/ CD31 (sfPECAM-1/CD31) is bound to the surface of pRBCs in suspension. This assay is not dependent on parasitemia and is in good agreement with the adhesion to transfected cell lines.
MATERIALS AND METHODS
Plasmodium falciparum laboratory strains. In vitro propagated P. falciparum isolates were cultured according to standard procedures 17 HUV was enriched from FCR3S1 by panning on human umbilical vein endothelial cells (HUVECs) six times.
Plasmodium falciparum patient isolates. Frozen parasite samples collected from children (mean age ϭ 4.2 years) with uncomplicated malaria attending the outpatient clinic of Kilifi District Hospital were thawed and put into culture. Blood was obtained after informed consent from the parents or guardians and the study was reviewed and approved by the Kenya Medical Research Institute ethical council and the Swedish Ethical Committee. For inclusion, a parasitemia of 1% or more was required and parasitemias ranged from 1% to 22%. Following thawing, the erythrocytes were cultured in RPMI 1640 medium in the presence of 10% malaria-naive serum until they matured into pigmented trophozoites. 17 Cell lines. Mouse L cells expressing PECAM-1/CD31 and Chinese hamster ovary cells (CHO cells) transfected with CD36 were grown as previously described. 13, 19, 20 The transfected cells were sorted by fluorescence-activated cell sorting (FACS) to 100% high expression.
Cell cytoadherence assay. The cytoadherence assay was performed essentially as described. 8 Briefly, transfected CHO or L cells were plated onto 13-mm 2 Thermanox coverslips (Nunc, Labassco, Sweden), precoated with 10 g/ml of fibronectin for 60 min at room temperature, and kept in a 24-well plate (Nunc). The cells were seeded at a density of 25,000 cells/well and grown for 24-36 hr before the assay. All experiments were done with unfixed cells. The culture medium was removed and replaced with 8 l of erythrocytes from a P. falciparum culture (2% hematocrit) resuspended in 400 l of binding medium (RPMI 1640 medium, 25mM HEPES, 25g/ml of gentamicin, 10% human serum, pH 6.8). Parasitemias were adjusted to range from 4% to 6%. The plates were incubated at 37ЊC for 60 min with gentle resuspension every 10 min. After incubation, unbound pRBCs were rinsed off, and the adhered infected erythrocytes were fixed with 1% Glutar-di-aldehyde (GDA) in phosphate-buffered saline for 30 min at room temperature. The slides were stained with 1% Giemsa for 30 min, and the number of bound pRBCs per 100 target cells was determined by light microscopy (1,000ϫ).
Labeling of soluble fluorescent PECAM-1/CD31. Construction of the human PECAM-1-Fc chimera has been described previously. 21 Human PECAM-1/CD31 was expressed in Cos cells as a fusion protein where the Fc-region of human IgG is joined with two PECAM-1/CD31 molecules resulting in a chimera where PECAM-1/CD31 is dimerized. 21 Human, recombinant, soluble PECAM-1/CD31 comprised of the extracellular portion of PECAM-1/CD31 produced in Cos cells was obtained from R&D Systems (Minneapolis, MN). Both PECAM-1-Fc and PECAM-1/CD31 were individually labeled with the fluorophore Alexa 488 (Molecular Probes, Eugene, OR) according to the instructions provided in the Alexa 488-labeling Kit. The recombinant soluble PECAM-1/CD31 and the PECAM-1-Fc chimera were labeled with the fluorophore Alexa 488 and purified on a polyacrylamide column according to the protocol provided by the manufacturer. The amount of unlabeled sPECAM-1/CD31 added was 1-1.5 mg. The concentration of fluorescent protein was subsequently determined by spectrophotometry, and three different labeling experiments yielded concentrations of fluorescent protein ranging from 600 to 800 gͦml with an average degree of labeling of 4.1 moles fluorescent dye per mole sPECAM-1/CD31.
Soluble fluorescent PECAM-1/CD31 suspension assay. Briefly, 30 l of live pRBCs were washed twice and resuspended in RPMI 1640 medium, pH 6.8 to the original volume before the sfPECAM-1/CD31 was added at different concentrations ranging from 0.1 to 200 g/ml. After incubation for 30 min at room temperature and protected from light (gentle resuspension after 15 min), the pRBCs were washed three times with RPMI 1640 medium, pH 6.8. Parasites were stained with ethidium bromide as described previously 22 and the fluorescence rate was assessed by counting the number of surface fluorescent pRBCs per total number of pRBCs in a Nikon (Tokyo, Japan) Optiphot-2 UV microscope, using a 10ϫ ocular and a 40ϫ lens.
Data analysis. The data were stored, formatted, and analyzed in Microsoft Excel (Microsoft Corp., Redmond, WA) and StatView 4.5 (Abacus Concepts, Inc., Berkeley, CA).
RESULTS
Characterization of labeled sPECAM-1/CD31 binding. The labeled sPECAM-1/CD31 bound avidly and produced bright fluorescence (Figure 1 ) when tested on a trophozoite stage infected RBC enriched for PECAM-1/CD31 binding (TM284S23). No binding to uninfected erythrocytes or ring stage-infected erythrocytes was seen. To optimize binding of sfPECAM-1/CD31 to the pRBC, we titrated various concentrations of labeled protein and found that fluorescence rate and intensity was maximized at a concentration of 100 g/ ml. The curve began to level off beyond that and further increases in concentration (200 g/ml) produced only minor changes (Figure 2A) . At that concentration, the fluorescence rate was approximately 60% in three independent experiments. With the PECAM-1-Fc chimera, the fluorescent rate was marginally higher, but followed the same pattern ( Figure  2A) .
Inhibition of pRBC adhesion to sfPECAM-1/CD31 using unlabeled sPECAM-1/CD31. The specificity of the binding was evaluated by competitive inhibition of surface fluorescence with unlabeled sPECAM-1/CD31 and could be competed out in a dose-dependent fashion but not by an unrelated proteins (bovine serum albumin, ICAM-1; Figure  2B ). The fluorescence rate detected at a concentration of 25 g/ml of fluorescent protein was set to 100% and the relative fluorescence in the presence of various concentrations of unlabeled sPECAM-1/CD31 was assessed. The binding of the PECAM-1-Fc chimera to pRBCs could be inhibited by sPECAM-1/CD31 and vice versa. Furthermore, sfPECAM-1/CD31 could inhibit binding of pRBCs to PECAM-1/CD31 transfected L cells in a cell-binding assay. A concentration of 1 g/ml gave 25% inhibition and 100 g/ml gave complete inhibition of binding to the transfected cells ( Figure  3A) .
Comparison of the suspension and cell assays. By running the suspension and cell assays in parallel on six different laboratory strains we were able to correlate the sf-PECAM-1/CD31 fluorescence rate and pRBCs adhesion to L cells ( Figure 3B ) and could calculate a correlation coefficient () of 0.943 between the two data sets (Spearman's rank correlation). Furthermore, enrichment for PECAM-1/ CD31 binding was made by panning pRBCs of the TM284 strain twice on L cells. Adhesion to L cells and the sfPECAM-1/CD31 fluorescence rate increased correspondingly; the cell assay increased from 125 to 362 pRBCs/100 cells whereas the fluorescence rate increased from 17% to 69%. Sensitivity to detect adhesion. To evaluate differences in sensitivity between the two assays we performed an experiment in which the supernatant containing uninfected erythrocytes and unbound pRBCs was collected after adhesion to L cells. The supernatant was then subjected to a repeated analysis where binding rates were recorded for L cell adhesion and the sfPECAM-1/CD31 fluorescence rate, respectively. We found a more pronounced decrease in the cell assay than in the suspension assay: the decrease in L cell binding was 89% (from 655 pRBCs/100 cells to 73 pRBCs/ 100 cells) and the decrease in the sfPECAM-1/CD31 fluorescence rate was 62% (69% to 26%).
Field isolates recognizing soluble PECAM-1/CD31. Forty frozen isolates taken from children with uncomplicated malaria were thawed and their ability to adhere to soluble PECAM-1/CD31 was assessed after in vitro culture. We found that 54% of the isolates bound to the receptor in suspension, with a mean fluorescence rate of 12.9% ranging from 1.1% to 44% (Figure 4 ). Twenty-eight percent (11 of 40) of the isolates showed a fluorescence rate greater than 10%. DISCUSSION We here present a novel way of detecting adhesion to pRBC receptors in a liquid phase assay using soluble, fluorescent PECAM-1/CD31 detected on the surface of live pRBCs. This assay has a great advantage over static cell adhesion assays in that all pRBCs are scored for binding independently of the parasitemia of the sample.
Because of the difficulty in studying the occurrence of endothelial cytoadhesion in humans, many experimental assay systems have been developed. The adhesive properties of pRBCs have been most commonly studied using endothelial cells or transfectants expressing the receptor of interest, but in vivo and ex vivo animal models have also been used. 23, 24 Flow-based cytoadhesion assays that take into account the shear stress exerted on adherent cells by circulating blood have also been developed by Cooke and others. 25 Purified receptors spotted onto plastic have been used, but it is known that plastic-bound protein may undergo conformational changes that can affect the adhesive properties, 20, 26 and though allowing accurate measurements, such assays may not generate useful data. Another problem occurs with the predominantly-used cell assays, since there is a pronounced dependency on parasitemia; the linear correlation between parasitemia and cytoadhesion makes the values obtained at low parasitemias difficult to interpret. 27 This, together with the fact that most patients have parasitemias less than 1%, has increased the demand for new techniques.
The suspension assay is quick and easy to perform, uses very small volumes of pRBCs, and shows no dependency on parasitemia, thus making it suitable for analyzing binding in large field materials. Previous studies using soluble fluorescent-labeled blood group A and heparin have similarly been successful in detecting the adhesion of pRBCs to these receptors 28, 29 (Heddini A and others, unpublished data). These assays are also useful in the development of flow cytometry-based analysis systems, where the adhesive properties between the pRBC and the receptor can be studied with higher objectivity and accuracy. Preliminary studies in Kilifi, Kenya, in which sCD31 and immunoglobulin binding was successfully measured by FACS, showed a very high correlation with assessment in the microscope (Kai O, unpublished data).
In contrast to the PECAM-1/CD31 assay developed here, it was not possible to detect binding of soluble ICAM-1 to pRBCs as in the previous studies of Craig and others. 30 A recombinant ICAM-1-Fc chimera was used that consists of the extracellular domains of ICAM-1 combined with the hinge region and C H 2 and C H 3 domains of the human IgG1 molecule and despite rather high concentrations, adhesion to immobilized ICAM-1 on plastic could not be blocked. It might be that the interaction between PECAM-1/CD31 and the pRBC is strong and the affinity is higher than that of soluble ICAM-1 with the pRBC, as is also suggested by similar differences in the interactions of pRBCs with cells expressing the two receptors (Heddini A and others, unpublished data). The fluorescence generated by sfPECAM-1/ CD31 is also stronger compared with that of fluorescein isothiocyanate-labeled blood group A or heparin, facts that further indicate the presence of an avid interaction between PECAM-1/CD31 and the pRBC.
However, the property of homophilic binding may cause soluble PECAM-1/CD31 molecules to aggregate so that differences in multimerization or aggregation could underlie the different observations with the various receptors. Indeed, aggregation of soluble CD31 has been observed in other experiments, where the aggregation was believed to enhance the avidity of binding. 21 This may also contribute to the very strong binding and bright fluorescence detected with soluble fluorescent CD31.
It was a major concern whether the surface fluorescence corresponded well to the cell adhesion since the kinetics of binding differs between the cell and the suspension assays, but in our experiments with laboratory strains, the surface fluorescence measured in the suspension assay correlated very well with cell binding in the cell assay. Furthermore, the results indicate that the suspension assay is more sensitive for the detection of binding, which could be explained by the independence of parasitemia, since the suspension assay allows accurate detection of pRBC adhesion even at parasitemias less than 1%.
We found that PECAM-1/CD31 is a receptor fairly commonly recognized by field isolates, implying that it may be of importance in the biology of the parasite. In this study, 50% of freeze-thawed wild isolates recognized PECAM-1/ CD31. No other endothelial receptor apart from CD36 has been shown to be so frequently recognized by wild P. falciparum isolates. This study shows that P. falciparum-infected erythrocytes bind soluble PECAM-1/CD31 and that detecting adhesion in suspension is both an accurate and quick way to study receptor-ligand interactions of patient isolates.
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